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els. The precise mechanism of these effects is unknown, but may be related
to the inhibition of platelet function and/or leukocyte recruitment.
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1931-1111 Platelet Activation and Aggregation by
Therapeutic Doses of Heparin
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Thus, heparin, but not argatroban, a direct thrombin inhibitor, induced P-
selectin expression and GP lib/lila activation in the basal state and following
agonist stimulation at low concentrations.
Control
Basal 1.80 ± 0.67 0.66 ± 0.114 0.011 ± 0.0024
ADP 701 ± 15.99 3.5 ± 1,48 101 ± 4.13 018±0074 43 ± 2.25
TRP 18.8 ± 16,45 081 ± 0.61 2.77 ± 2.02 0.05 ± 0.039 2.2 ± 1.84
Heparin
Basal 3.60 ± 1,42* 1.00 ± 0.292* 0.018 ± 0.0047 t
ADP 76.6 ± 12,49* 4.2 ± 1.70* 13.2 ± 4,43* 0.24 ± 0.087* 88 ± 3.06t
TRP 32.9 ± 25.60* 1.5 ± 1.17* 3.32 ± 2.24* 0.06 ± 0.039 6.2 ± 1.84*
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This single-blind, placebo-controlled study evaluated the tolerability and
pharmacodynamic (PO) response of the first dose of the oral GPlib/llia re-
ceptor antagonist, SC-54684A (ethyl 3S-[[4-[[4(amino-iminomethyl)phenyl]a-
mino]-l,4-dioxobutyl]amino]-4-pentynoate, monohydrochloride). SC-54684A
(SC) is the pro-drug of the active compound, SC-54701A. Six healthy male
subjects received 50 mg of SC (free base) and 2 received placebo (PBO). Re-
sults of the inhibition to AOP (20 I'M) induced platelet aggregation are shown
below:
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Effects of Inhibition of Nitric Oxide Synthesis in
Proximal and Distal Segments in Patients with
Normal Arteries and in Patients with Coronary
Artery Disease
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Bleeding time increased a mean of 5.6 fold at 4 hrs post-dose and returned
to within normal limits at 8 hrs after dosing. No significant changes in lab
values or bleeding complications occurred. Peak serum concentrations co-
incided with peak PO effects of inhibition of platelet aggregation.
Conclusion; SC-54684A has a rapid onset of potent inhibition of platelet
aggregation that is sustained for up to 10 hours after dosing.
1931-11412.3 ± 2.07*2.0 ± 2.61
Max%BIPL%BI
2.30 ± 0.75 0.82 ± 0.192* 0.015 ± 00041*
691 ± 1962 3.5± 1.75 11.4±4,42 0.21 ±0.085
21.0 ± 14.23 0.88 ± 0.56 2.48 ± 1.12 0.05 ± 0.021
PAC-1
PL%
*p < 0.05 and t p < 001 vs Control
Argatroban
Basal
ADP
TRP
To understand better the complex interaction of heparin with platelets,
this study investigated platelet function by flow cytometry and aggregation
curves, with and without the drug, in 7 pts with unstable angina and 7 normal
individuals. Method and Results: Platelet aggregation induced by low doses
AOP (0.3125 /LM) and thrombin receptor agonist peptide (TRAP 0.625 I'M)
was quantified in platelet-rich plasma (PRP) before and after the administra-
tion of intravenous heparin at doses prolonging the aPTI 2.5 x control and
also after the addition in whole blood, ex vivo of therapeutic concentration of
heparin (0.2 U/mlj, argatroban (1 ng/ml) or of an equal volume of normal saline
(Control). Platelet activation was evaluated by the percentage of fluorescein
positive platelets (PL%) and the binding index per platelet (BI), using antibod-
ies directed against P-selectin (C062) and activated GP lib/lila receptor (pAC-
1). Following intravenous heparin, the maximal shift in platelet aggregation
(Max%) increased from 6.3 ± 3.6 to 11.6 ± 8.5 with AOP and from 4.4 ± 3.0
to 11.9 ± 5.2 (p < 0.05) with TRAP. The results of the ex vivo studies (x ± SO)
were:
PRP optical aggregation (%) Before AfterASA
1 h. 24 h
ADP (5/LM): L-ASA 73 ± 21 50 ± 14* 45± 15*
H-ASA 65 ± 23 54 ± 17* 52 ± 16*
PI 69 ± 18 72 ± 22 69 ± 14
Col (3 /Lg/ml): L-ASA 64 ± 19 33 ± 13* 36 ± 18*
H-ASA 60± 16 32 ± 17* 34 ± 14*
PI 55 ± 13 56 ± 18 57 ± 14
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d'Hebron, Barcelona, Spain; Montreal Heart Institute, Montreal, Canada
Prompt inhibition of platelet aggregation is important in acute coronary syn-
drome and before an intervention procedure. To determine whether a single
low dose of iv aspirin inhibits platelet aggregation, twenty-seven healthy vol-
unteers (7 F and 20 Mj, mean age 43.5 years, were randomized double-blind
to a single iv low dose of aspirin OL-Iysine (L-ASA) equivalent to 2 mg!kg of
aspirin, high dose (H-ASA) equivalent to 10 mg!kg, or placebo (PI). Platelet ag-
gregation were performed before and 1 hand 24 h after drug administration,
in whole blood (WB) using electrical impedance and in platelet-rich plasma
(PRP) by optical light transmittance. Baseline WB platelet aggregation (Col 3
ILg/ml) was the same with L-ASA, H-ASA and PI (24 ± 5, 23 ± 3 and 24 ± 4rl
respectively) and decreased significantly more with L-ASA and H-ASA than
with PI after 1 h.(17± 6, 15± 7 and 21 ±5rl p < O.Ol)and 24h(17 ± 7, 16±
6 and 25 ± 4rl P < 0.01). Results in PRP were similar:
Inhibition of nitric oxide synthesis causes a decrease in basal diameter of dis-
tal epicardial coronary arteries in patients (pts) with normal coronary arteries
(NCA). The effects of inhibition of nitric oxide synthesis with NG-monomethyl-
L-arginine (LNMMA) in atheromatous coronary arteries was evaluated in 13
pts with chronic stable angina (aged 57 ± 7 years, 11 males) due to angio-
graphically documented coronary artery disease and in 8 pts (aged 50 ± 5
years, 4 males) with angiographically NCA. LNMMA was infused intracoro-
nary at 4,8 and 16/Lmol/min each for 4 minutes. In response to low LNMMA.
4lLmollmin, there was a significant (p < 0.05) reduction in luminal diameter
of both proximal (from 3.49 ± 0.28 to 3.35 ± 0.28 mm) and distal (from 1.33
± 0.07 to 1.23 ± 0.06 mm) segments in patients with NCA. In patients with
atheromatous arteries there was a reduction in diameter of the distal seg-
ments (from 1.44 ± 0.06 to 1.33 ± 0.07 mm) but no change occurred in the
proximal segments (from 2.95 ± 0.16to 2.89 ± 0.16 mm). In response to high
LNMMA. 16ILmol/min, there was a significant (p < 0.01) reduction in luminal
diameter of both proximallfrom 2.53 ± 0.27 to 2.33 ± 0.26 mm) and distal
(from 1.10 ± 0.06 to 0.99 ± 0.06 mm) segments in the pts with NCA. In the
pts with atheromatous arteries the distal segments decreased in diameter
(from 1.32 ± 0.07 to 1.17 ± 0.06 mm) but no change occurred in the proximal
segments (from 3.16 ± 0.12 to 3.08 ± 0.14 mm). The magnitude of the distal
vessel constriction was similar in both the patients with normal and in those
with atheromatous arteries (-9.6 ± 2.1 % and -10.9 ± 2.6% respectively, p
= NS). In conclusion in pts with chronic stable angina due to coronary artery
disease inhibition of basal nitric oxide synthesis causes distal coronary artery
vasoconstriction, but it has no effect on proximal segments.
1931-1121 A Low-dose Intravenous Aspirin, Bolus Injection,
Effectively Inhibits Platelet Aggregation
1931-1151 Phase I Studies on Inogatran, a New Selective
Thrombin Inhibitor
*p < 0.001 IANOVA test} respect to PI and the baseline values
No differences in response were observed between the two doses of aspirin
and no significant changes occurred between 1 and 24 hours in any group.
Effective inhibition of platelet aggregation is thus achieved within 1 hour
after the administration of low-dose 2 mg!kg of ivaspirin.
Ann-Catrine Teger-Nilsson, Ulf Eriksson, DaVid Gustafsson, Ruth Bylund,
Gunnar Fager, Peter Held. Astra Hassle AB, 5-431 83 M6lndal, Sweden
Inogatran is a new, synthetic, active site inhibitor of thrombin with a molecular
weight of 439 dalton. Inogatran (pINNI selectively, rapidly and competitively
binds thrombin with a Ki value of 15 nmol/l. In vitro it doubles the plasma
